QIAGEN Significantly Expands its Portfolio of Licenses to real-time PCR
Two New Licenses Added to Technology Portfolio targeting Molecular Diagnostics
The two separate and independent agreements provide QIAGEN with access to a major portfolio of additional patent and marketing rights, which were not covered by the original licensing agreements with Roche. Through these agreements QIAGEN is broadening its technology portfolio to assay technologies and diagnostic tests using almost any basic PCR patent and real-time PCR patent rights related to reagents and methods for practicing PCR and real-time PCR for IVD.
Through the license extension agreement with Roche QIAGEN is now licensed under all real-time polymerase chain reaction (PCR) patents and pending patent applications owned or controlled by Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd, Basel, Switzerland. The agreement with Roche includes, but is not limited to, additional enzyme patent rights further PCR improvement patent rights and pathogen specific patent rights.
In addition, QIAGEN obtained a license from Ortho Clinical Diagnostics to patents related to a taq-polymerase antibody mediated method used to initiate PCR. This is often referred to as a "Hot-Start" technology because it accelerates the activation of PCR enzymes and thereby accelerates the start of the PCR process. The license gives QIAGEN rights in the fields of in research, applied testing and IVD.
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.